Physician profile
David Soltanpour
NPI 1639274475
$619.16
in general payments reported to CMS, 2019-2025
14 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $97.10 · 2021: $19.36 · 2022: $198 · 2023: $98.58 · 2024: $21.06 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $207.11 | 2022-2023 | Tyrvaya |
| Csl Behring | $97.59 | 2025 | Andembry, Haegarda |
| Allergan, INC. | $72.35 | 2020 | |
| Paratek Pharmaceuticals, INC. | $45.23 | 2023-2024 | Nuzyra |
| Alcon Vision LLC | $35.92 | 2022 | |
| Sight Sciences, INC. | $29.44 | 2022 | |
| Viiv Healthcare Company | $20.64 | 2025 | Apretude |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.36 | 2021 | |
| Phadia US INC. | $17.94 | 2025 | Immunocap |
| Alk-Abello, INC | $17.76 | 2025 | Grastek, Odactra, Ragwitek |
| Tarsus Pharmaceuticals, INC. | $17.48 | 2025 | Xdemvy |
| Harrow Eye, LLC | $13.59 | 2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $13.12 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Soltanpour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.